Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding (OTCMKTS:VXRT)
Vaxart (VXRT) Q2 2026 earnings call recap: Phase IIb oral COVID pill vaccine safety update, BARDA funding, cash runway, and 2027 catalystsâread now.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
Vaxart (VXRT) Q2 2026 earnings call recap: Phase IIb oral COVID pill vaccine safety update, BARDA funding, cash runway, and 2027 catalystsâread now.
Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding (OTCMKTS:VXRT) | Seeking Alpha
Earnings Call Insights: Vaxart, Inc. (VXRT) Q2 2026
Management View
"The second quarter and recent weeks marked a pivotal period of execution and progress for Vaxart." (President, CEO & Director Steven Lo)
"In July, we achieved a key milestone in our
Seeking Alpha's Disclaimer:
This article was automatically generated by an AI tool based on content available on the Seeking Alpha website, and has not been curated or reviewed by humans. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of such articles cannot be guaranteed. This article is intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Quick Insights
How will BARDA's control affect Vaxart COVID-19 trial data timing?
BARDA has final approval over timing and content of all Vaxart main cohort trial data readouts, creating disclosure and reporting dependencies beyond company control.
How solid is Vaxart's financial runway given reported losses?
Vaxart projects funding through the second quarter of 2027 via its cash and $25 million share purchase agreement, but recent quarters shifted from net income to net loss, highlighting a need for disciplined financial management and potential dilution risk.
What is the status and outlook for Vaxart's norovirus program partnership?
The norovirus program partnership is ongoing with continued partner interest, but future trial timelines are contingent on securing funding or a partner, with management emphasizing it's premature to provide start dates due to funding uncertainty.
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
AIXC targets August 2026 RoboShare rentals in Los Angeles as liquidity remains constrained (NASDAQ:AIXC)
AIXC Q2 2026 earnings call highlights: RoboShare LA launch, August revenue target, liquidity risks, and expense cuts.
Bimini outlines NOL runway to $5.5M by end of 2028 while integrating TJIMâs $1.7B AUM platform (OTCMKTS:BMNM)
Bimini Capital (BMNM) Q2 2026 earnings call highlights TJIM acquisition impact, advisory revenue growth, NOL timeline and buybacks amid rate volatilityâread...
Gladstone Investment aims to deploy at least $116M in first 6 months as SFEG exit advances (NASDAQ:GAIN)
Gladstone Investment (GAIN) Q1 2027 earnings call recap: NII, NAV, SFEG exit potential, SOFR sensitivity, deals & dividend coverageâread key takeaways.
Embecta forecasts $1.80-$1.90 FY2026 adjusted EPS while raising adjusted operating margin to 23.5%-24% (NASDAQ:EMBC)
Embecta (EMBC) Q3 FY2026 earnings call recap: revenue rebound, Owen Mumford integration, raised EPS/margin guidance, and risks.